Combined Treatment with Micro-Focused Ultrasound with Visualization and Intradermal Incobotulinumtoxin-A for Enlarged Facial Pores: A Retrospective Study in Asians
DOI: https://doi.org/10.2147/CCID.S402001
2023-05-15
Abstract:Je-Young Park, 1, &ast Ji Su Lee, 2, &ast Soo Ran Lee, 2 Dong Hun Lee 2– 4 1 Apkoo-Jung Oracle Dermatology Center, Seoul, Republic of Korea; 2 Department of Dermatology, Seoul National University Hospital, Seoul, Republic of Korea; 3 Department of Dermatology, Seoul National University College of Medicine, Seoul, Republic of Korea; 4 Institute of Human-Environment Interface Biology, Medical Research Center, Seoul National University, Seoul, Republic of Korea &astThese authors contributed equally to this work Correspondence: Dong Hun Lee, Department of Dermatology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea, Tel +82-2-2072-4916, Fax +82-2-742-7344, Email Background: Despite the increasing need for the improvement of enlarged facial pores, the treatment remains challenging. A few previous studies have reported the effects of micro-focused ultrasound with visualization (MFU-V) or intradermal incobotulinumtoxin-A (INCO) on enlarged facial pores. Objective: To evaluate the efficacy and safety of combined treatment with superficial MFU-V and intradermal INCO for enlarged facial pores. Methods: This single-center retrospective study included 20 patients treated with MFU-V and intradermal INCO to improve enlarged facial pores. Outcomes were evaluated 1, 4, 12, and 24 weeks after a single session of the combined procedure. Pore count and density were objectively quantitated using a three-dimensional scanner, and improvement was assessed using the physician and patient Global Aesthetic Improvement Scale (GAIS). Results: The mean pore count and density decreased after one week and decreased by up to 62% until 24 weeks. After one week, almost all patients (100% in physician GAIS and 95% in patient GAIS) showed improvement with a grade 3 (much improved) or higher. All adverse events were transient. Conclusion: Combined treatment with MFU-V and intradermal INCO could be effective and safe for reducing enlarged facial pores; the improvements can be sustained for up to 24 weeks. Keywords: pores, enlarged facial pores, incobotulinumtoxin-A, micro-focused ultrasound with visualization 'Enlarged facial pores' are visible topographic features on the skin surface, corresponding to enlarged openings of pilosebaceous follicles. 1 They are one of the greatest cosmetic concerns for many individuals, as evidenced by numerous cosmetic products designed to conceal enlarged pores. 2 Enlarged facial pores can deteriorate facial skin quality, negatively affecting an individual's appearance and self-image, which can impede social interaction and ruin the quality of life. 2 Although the pathogenesis of enlarged facial pores is still unclear, three factors are thought to be the main pathology: 1) high sebum production, 2) decreased skin elasticity around pores, and 3) increased hair follicle volume. 1,3–7 Other factors, including chronic recurrent acne, sex hormones, and skin care regimens, such as inappropriate use of cosmetics, washing habits, and sun exposure, also affect pore enlargement. 1,8 Diverse treatment methods to reduce pores have been reported, including topical/systemic retinoids, chemical peeling, botulinum toxin, filler, and energy-based devices, such as intense pulse light, diode, radiofrequency, fractional laser, and micro-focused ultrasound with visualization (MFU-V). 1,2,9–19 However, there are no established treatments, and treatment of enlarged facial pores is still challenging. 1,9 Particularly, enlarged pores easily recur after treatment discontinuation, which negatively impacts treatment satisfaction. 20 Given the multifactorial pathophysiology of enlarged facial pores, combining treatments might be more effective than a single modality. 1 MFU-V and intradermal incobotulinumtoxin-A (INCO) have been shown to independently improve enlarged pores to varying extents, 10–19 but the combined use of both modalities has not been assessed. Both modalities are reported to involve minimal downtime, potentially making this combination a suitable treatment option for patients who cannot afford long recovery periods. As such, this study aimed to investigate the efficacy and safety of combined treatment with MFU-V and INCO for enlarged facial pores in Asians. This was a single-center, retrospective clinical study. The patients who visited Apkoo-Jung Oracle Dermatology Center between April and November 2021 and received facial treatments with combined intradermal INCO and MFU-V for enlarged facial pores were reviewed. Among these patients, those who had regu -Abstract Truncated-
dermatology